In June an independent advisory committee recommended the FDA not approve MDMA assisted therapy for PTSD. This came as a surprise to many working in and following the field of psychedelic assisted therapy. It also raised questions as to where the field is at and what challenges still exist.

To provide some context and perspective on this decision and some of the specific criticism raised during the hearing Henrik Jungaberle, a psychedelic and public health researcher in Berlin joined the show.

This is the only link you need to subscirbe and never miss an episode of Two Brad For You. Please do rate and review it really helps us out.

If you'd like to support the show with currency click here. We are grateful for that too. Finally, you can check out the website here.

Many thanks to Freak Motif for the music and Sebastian Abboud for the logo.

• The MIND Foundation
• Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design - ScienceDirect
• Treatment with psychedelics is psychotherapy: beyond reductionism - The Lancet Psychiatry
• Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ) - Journal of Psychopharmacologyent...
• Was the FDA Panel Right to Recommend Against MDMA Approval? - MedPage Today
• Psychiatric Drug Developers Make Recommendations Following Lykos Adcomm - BioSpace
• An emotional public hearing on MDMA: ‘Today you will vote on whether my friends live or die’